Mechanism of action describes the process by which a molecule, such as a drug, functions to produce a pharmacological effect. A drug’s mechanism of action may refer to its effects on a ...

LIB Therapeutics announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lerodalcibep, a treatment aimed at lowering low-density ...

Lerodalcibep could be a key treatment option for patients needing additional LDL-C reduction beyond existing therapies. Credit: Katernya Kon via Shutterstock. LIB Therapeutics announced that the US ...

Despite much research, the exact molecular mechanism underlying stator function is yet unclear. In a new study, researchers analyzed the flagellar motor in Vibrio alginolyticus using cryo-electron ...

State Key Laboratory of Heavy Oil Processing, College of Chemistry and Chemical Engineering, China University of Petroleum (East China), Qingdao 266580, China ...

A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

药明康德传来重磅消息：LIBTherapeutics公司今日宣布，其潜在的“最佳治疗”药物lerodalcibep已经获得美国FDA的生物制品许可申请（BLA）受理。该药物专 ...

药明康德传来重磅消息：LIBTherapeutics公司今日宣布，其潜在的“最佳治疗”药物lerodalcibep已经获得美国FDA的生物制品许可申请（BLA）受理。该药物专为降低低密度脂蛋白胆固醇（LDL-C）而设计，目标患者群体包括动脉粥样硬化性心血管疾病（ASCVD）患者，以及高 ...

在刚刚发布的消息中，药明康德的LIBTherapeutics宣布，该公司正在开展一种名为lerodalcibep的创新疗法，它已经获得了美国FDA的受理。该疗法旨在降低ASCVD患者的LDL-C水平，并专为那些面临极高或高ASCVD风险的患者设计。这项全新的疗法为患者提供了一种便捷的治疗 ...

LIB Therapeutics公司今天宣布，美国FDA已受理潜在“best-in-class”在研疗法lerodalcibep的生物制品许可申请（BLA），lerodalcibep旨在降低低密度脂蛋白胆固醇 ...